The Insomnia drugs in development market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Insomnia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Insomnia and features dormant and discontinued products.

GlobalData tracks 41 drugs in development for Insomnia by 41 companies/universities/institutes. The top development phase for Insomnia is phase ii with 13 drugs in that stage. The Insomnia pipeline has 39 drugs in development by companies and two by universities/ institutes. Some of the companies in the Insomnia pipeline products market are: Zelira Therapeutics, Bod Science and Idorsia Pharmaceutical.

The key targets in the Insomnia pipeline products market include Cannabinoid Receptor 2 (CB2 or CX5 or CNR2), Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1), and Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2).

The key mechanisms of action in the Insomnia pipeline product include Cannabinoid Receptor 1 (CB1 or CANN6 or CNR1) Agonist with eight drugs in Phase II. The Insomnia pipeline products include seven routes of administration with the top ROA being Oral and two key molecule types in the Insomnia pipeline products market including Small Molecule, and Biologic.

Insomnia overview

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress, and shift working.

For a complete picture of Insomnia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.